



100% Capital Protected – 6% p.a. Conditional Coupon (USD)

Subscription Deadline: 22 December 2016

This product is designed for investors looking to participate in the performance of four UK Blue Chip Stocks, looking to receive a possible income from their investment, and require a 100% capital guarantee.

PRODUCT TERMS

ISSUER	Natixis	STRIKE DATE	22 December 2016
RATING	S&P A / Moody's: A2 / Fitch: A	ISSUE DATE	10 January 2017
TERM	5 Years	FINAL VALUATION DATE	22 December 2021
UNDERLYING STOCKS	Tesco, Barclays, BP, GlaxoSmithKline	MATURITY DATE	30 December 2021
CONDITIONAL COUPON	6% p.a. Conditional Coupon	CAPITAL PROTECTION	100% Capital Protected

KEY FEATURES

- **100% Capital Protected**
- **Conditional Coupons of 6% p.a.**
- **Coupon payments linked to the performance of four UK Blue Chip stocks**
- **100% of invested capital returned at maturity regardless of the performance of the underlying stocks**

INVESTMENT DESCRIPTION

- **Capital Protection** – Capital is protected regardless of the performance of the underlying stocks
- **Conditional Coupon** – An annual coupon of 6% is paid if each of the underlying stocks are above 100% of the Strike Level on each annual Coupon Observation Date
- **Maximum Potential Return** of 30% over the life of the product

CURRENCY	ISIN CODE	CONDITIONAL COUPON AMOUNT	COUPON HURDLE
USD	XS1408706684	6% p.a.	100%

COUPON OBSERVATION DATES

Conditional Coupon payments may be made following these annual observation Dates:

- 22 December 2017
- 21 December 2018
- 20 December 2019
- 22 December 2020
- 22 December 2021

PAYOFF AT MATURITY

There are 2 potential outcomes when the product reaches its scheduled Final Valuation Date:


- If the least performing stock is greater than 100% of its initial Strike Level, the Note returns 100% plus a 6% Coupon
- If one or more Underlying Stock closes lower than 100% of the initial Strike Level, the Note still returns 100% of capital

RISKS & DRAWBACKS

- Capital is at risk in the case of bankruptcy or default by the Issuer



INVESTMENT ROUTE MAP



PLACING AN ORDER

Orders may be placed with the Structured Products Team at Market Securities via email or telephone. Here are the key details you will need:

ISIN CODES	XS1408706684
EMAIL	Struct_Orders@Market-Securities.com
TELEPHONE	+ 44 (0)20 3192 1039
SUBSCRIPTION DEADLINE	22 December 2016
ISSUE DATE	10 January 2017
DENOMINATIONS	THE SECURITIES TRADE IN \$1,000 DENOMINATIONS

WHO CAN INVEST IN THESE NOTES?

- Professional Investors
- Life Insurance Companies
- Corporate and Institutional Investors
- Those willing to be exposed to the credit risk of the Issuer



THE UNDERLYING STOCKS

Tesco plc

Tesco plc, through its subsidiaries, operates as a food retailer. The Company offers online retailing, brick and mortar supermarkets, and a private-label brand of products. Tesco provides its services primarily throughout Europe, with additional activities in Asia and the Americas.


	2011	2012	2013	2014	2015
Annual Return	-5.07%	-16.72%	-0.49%	-43.47%	-20.90%



Barclays plc

Barclays plc is a global financial services provider engaged in retail banking, credit cards, wholesale banking, investment banking, wealth management and investment management services.


	2011	2012	2013	2014	2015
Annual Return	-32.72%	49.05%	12.19%	-10.46%	-10.10%



BP plc

BP plc is an oil and petrochemicals company. The Company explores for and produces oil and natural gas, refines, markets, and supplies petroleum products, generates solar energy, and manufactures and markets chemicals. BP's chemicals include terephthalic acid, acetic acid, acrylonitrile, ethylene and polyethylene.

	2011	2012	2013	2014	2015
Annual Return	-1.08%	-7.75%	14.89%	-15.79%	-13.87%



GlaxoSmithKline plc

GlaxoSmithKline plc is a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

	2011	2012	2013	2014	2015
Annual Return	18.67%	-9.28%	20.71%	-14.61%	-0.22%





IMPORTANT INFORMATION

This sales brochure is confidential and issued for information purposes only. It is directed exclusively at Professional Customers and Eligible Counterparties as defined by the Markets in Financial Investments Directive. It does not constitute an offer or invitation to enter into any type of financial transaction in securities.

Whilst the information set out in this sales brochure is reflective of the terms, no warranty is made that the information contained is accurate or complete and so should not be relied upon as such.

This investment product is a complex structured financial instrument and involves a high degree of risk. It is intended only for investors who understand and are capable of assuming all risks involved. Before entering into any transaction, an investor should determine if this product suits his or her particular circumstances and should independently assess (with his or her professional advisers) the specific risks (maximum loss, currency risks, etc.) and the legal, regulatory, credit, tax and accounting consequences. The Issuer makes no representation as to the suitability or appropriateness of this investment product for any particular investor or as to the future performance of this investment product.

All of the details set out in this sales brochure pertaining to the securities comprise a mere summary, and are not a complete description of the securities. Investors should read the formal terms and conditions of the Securities and any offering circular or other disclosure document prepared by or on behalf of the Issuer in respect of the Securities including, if applicable, a prospectus (the "Securities Documentation"). For avoidance of doubt, in the event of any conflict between information set out in this sales brochure and information set out in the Securities Documentation, the terms of the Securities Documentation shall prevail. The Securities Documentation is available from Kyte Broking Ltd upon request.

This sales brochure has not been prepared or reviewed by the Issuer of the underlying securities or any of their respective affiliates and neither the Issuer nor any of their respective affiliates or any of their respective directors, officers or agents accept any responsibility or liability for the contents of this sales brochure.

For the avoidance of doubt, investors are the clients of Kyte Broking Ltd. No Investor or other customer of Kyte Broking Ltd shall become a direct or indirect customer of the Issuer or any of its affiliates by subscribing for or purchasing Securities.